MVM
Medicxi Ventures Management Portfolio holdings
AUM
$427M
This Quarter Return
+49.92%
1 Year Return
+42.94%
3 Year Return
+262.94%
5 Year Return
+109.92%
10 Year Return
–
AUM
$357M
AUM Growth
+$357M
(+53%)
Cap. Flow
+$21.5M
Cap. Flow
% of AUM
6.03%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
2
Reduced
1
Closed
–
Top Buys
| 1 |
Phathom Pharmaceuticals
PHAT
|
$18.3M |
| 2 |
NewAmsterdam Pharma
NAMS
|
$10.3M |
Top Sells
| 1 |
Vaxcyte
PCVX
|
$7.08M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNTA
1
Centessa Pharmaceuticals
CNTA
$2.25B
| $124M | 34.62% | 19,963,157 | – | – |
|
|
2
Vaxcyte
PCVX
$4B
| $65.7M | 18.41% | 1,315,435 -141,865 | -10% | -$7.08M |
|
|
3
Phathom Pharmaceuticals
PHAT
$864M
| $53.9M | 15.09% | 3,760,869 +1,276,595 | +51% | +$18.3M |
|
4
Merus
MRUS
$4.98B
| $42.1M | 11.8% | 1,600,000 | – | – |
|
5
Aura Biosciences
AURA
$389M
| $37.5M | 10.52% | 3,039,892 | – | – |
|
|
6
NewAmsterdam Pharma
NAMS
$2.71B
| $34.1M | 9.56% | 2,869,565 +869,565 | +43% | +$10.3M |
|